Asia Pharma R&D Leaders Summit 2017
March. 21 ( Tuesday ) to March 22 ( Wednesday ), 2017
Sponsor
Website:
Founded in 2004, Sundia MediTech Company Ltd. is a leading China-based CRO providing a broad range of high-quality, cost effective drug discovery and development services. Capitalizing on its broad service offerings, experienced scientists and advanced research facilities and equipment, Sundia helps its customers discover and develop novel drug candidates efficiently. Sundia currently provides services to over 160 customers globally, including a vast majority of the top 20 pharmaceutical and biotechnology companies in the world, as well as fast-growing biotechnology and specialty pharmaceutical companies and renowned academic and research institutions. Sundia currently boasts an experienced and strong R&D tem, comprised of over 700 employees, of over 70% have post-graduate degrees and an average of 15 years of relevant industry experience. The Company conducts its laboratory and development activities in three primary facilities in China: a) Shanghai Zhangjiang Hi-Tech Park; b) Shijiazhuang; and c) Taicang.
CrownBio is a Cutting Edge Translational Technology Company Making Precision Medicine a Reality
CrownBio brings clarity to drug discovery around the world by helping biopharmaceutical companies solve some of today's most pressing challenges in oncology, cardiovascular, and metabolic disease Drug Discovery.
Our premier Translational Platforms for cancer and metabolic disease help our clients accelerate their new drug development programs. CrownBio develops world-leading preclinical efficacy models and provides both in vitro and in vivo testing services and preclinical research products. We are a global company with facilities across the world in the United States, United Kingdom, China, and Taiwan.
We Help our Clients Accelerate Drug Discovery, Gain Insight and De-Risk Ushering Candidates into the Clinic
As a comprehensive solution provider, CrownBio helps reveal the best clinical possibilities with our proprietary HuPrime®, HuKemia®, HuBase™, HuMark™, HuTrial™, and HuSignature™ platforms enabling the rapid translation of a lead compound into a successful clinical candidate.
CrownBio's cutting-edge, proprietary, Translational Technology Platforms provide robust and scientifically sound end-to-end solutions for preclinical drug development.
The Premier Translational Platforms for Advanced Drug Discovery From large-scale in vitro and in vivo efficacy studies of drug candidates, to running surrogate trials in tandem with human clinical trials, CrownBio's well-characterized Translational Platforms deliver comprehensive and catered solutions for biopharmaceutical companies. By providing the data needed to inform and accelerate oncology and cardiovascular and metabolic disease (CVMD) therapeutic development, CrownBio helps our clients make smarter decisions about their drug candidates.
With more experience than anyone in the industry, CrownBio's global resources help customers answer the most challenging questions about human biology.
CrownBio's portfolio of cutting edge technologies includes the world's largest commercial collection of validated Patient-Derived Xenograft (PDX) models. At CrownBio we are seeking to recapitulate the diversity and complexity of human cancer biology in the laboratory.
Our Translational Technology Platforms are helping our clients make precision medicine a reality.
HD Biosciences Co., Ltd. is a biology-focused preclinical drug discovery contract research organization (CRO) with operation facilities in Shanghai, China and La Jolla, California. The company offers comprehensive service platforms around target validation, plate-based pharmacology, hit identification and lead discovery, therapeutic antibody discovery, in vivo pharmacology, as well as other research and development services. The company currently collaborates with eight of the world’s ten largest pharmaceutical companies and has established strategic partnership in many key R&D areas with the impacts to portfolio development. The strong scientific expertise, high quality and consistent deliveries, which constantly meet or exceed client’s expectations, have earned the company a great reputation in the industry and helped the company to build its widely recognized leadership in preclinical contract research services.
ScinoPharm is a leading process R&D and active pharmaceutical ingredients (API) manufacturing service provider to the global pharmaceutical industry. With its FDA approved cGMP production facilities in Taiwan and China, ScinoPharm offers services ranging from custom synthesis of early phase clinical materials to commercial production. ScinoPharm serves over 300 customers worldwide, including most brand and all top-ten generic pharmaceutical companies. Specialized in high potency APIs, ScinoPharm has developed a broad product portfolio in the oncology category and has filed DMFs in as many countries as possible, at >743 DMF registrations worldwide, with 52 in the US. ScinoPharm has built extensive technical expertise in the fields of small molecules and peptides over the last 19 years. The company’s strict adherence to intellectual property protection and compliance with environmental, health and safety codes makes it a preferred API supplier for major pharmaceutical companies as well as new drug development companies in contract research and manufacturing services. Already the leader in providing oncology APIs to regulated markets worldwide, ScinoPharm has been expanding into the field of oncological injectable formulations, which will provide a vertically integrated, one-stop-shop service for our existing API customers. For more information, please visit the company’s web site at http://www.scinopharm.com
Asia Pharma R&D Leaders Summit 2017  |  Telephone: +86 21 6172 6970  |  E-mail: kevin.tan@deliver-consulting.com
© 2016 Asia Pharma R&D Leaders Summit 2017- All rights reserved